China-Based Heparin Prompts Outsourcing Worries
This article was originally published in PharmAsia News
Executive Summary
The problems with Chinese-made ingredients for the heparin blood-thinner drug highlight one peril of drug makers outsourcing production elements. Heparin recalls have been announced in six countries where regulators have been moved to consider the source, China, which itself has increased drug safety efforts. China and India are among developing countries still developing their systems for safeguarding drug production. One American safe-medicine advocate said the heparin problem was "just the tip of the iceberg" where sensitive drugs are concerned. (Click here for more
You may also be interested in...
EU Parliament Stricter Than Council On Medicines And Medical Devices Packaging
The EU Parliament's Environment, Public Health and Food Safety committee takes a compromise position with regards to the Packaging and Packaging Waste Directive. Medicines and medical devices should be exempt, but only until 2035, at which point the European Commission should check whether the development of materials and the recycling process have progressed, and may adjust this exemption accordingly.
Stay Or Exit? Global Health Players Ponder New China Trajectory
It's again the time of year when global CEOs descend on China's capital to discuss strategies. This year, however, the mood is different.
Report Finds Digital Diabetes Tools Deliver No ‘Meaningful Clinical Benefits'
A new report from health economics group the Peterson Health Technology Institute found that apps to help patients manage their blood sugar levels delivered few of the promised benefits. However, a digital therapeutics industry association says PHTI’s research cast too narrow a net.